At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 166 enrolled
Drug / intervention
parecoxib sodium +2 moredrug
Likely dose
parecoxib sodium 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tumor Hospital of Guangxi Medical University, China
In Brief
A Phase 4 clinical trial evaluating parecoxib sodium, flurbiprofen, and 1 other intervention for Postoperative Shivering. Completed, enrolled 166 participants across 1 site.
Detailed Summary
Shivering is an early postoperative complication during the postoperative recovery period, and there is no clear consensus about the best way for its prevention. The aim of the study was to compare the efficacy and accompanying side effects of prophylactic flurbiprofen with that of parecoxib or placebo for reducing postoperative shivering.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostoperative Shivering
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartApr 2014
Primary CompletionApr 2015
First PostedOct 2015
TodayJul 2026
First PostedOct 7, 2015
Enrollment StartApr 1, 2014
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 10.7 years ago
Interventions
parecoxib sodiumdrug
parecoxib sodium 40mg
flurbiprofendrug
flurbiprofen 50mg
salinedrug
normal saline